HighTower Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

HighTower Advisors’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-19,129	Closed	-$58K	–	2498
2018 Q4	$58K	Sell	19,129 -127	-0.7%	-$440	﹤0.01%	2019
2018 Q3	$81K	Hold	19,256	–	–	﹤0.01%	2087
2018 Q2	$74K	Sell	19,256 -19,065	-50%	-$127K	﹤0.01%	2035
2018 Q1	$243K	Hold	38,321	–	–	﹤0.01%	1777
2017 Q4	$310K	Hold	38,321	–	–	﹤0.01%	1694
2017 Q3	$438K	Buy	+38,321	New	+$403K	﹤0.01%	1495
2017 Q2	–	Sell	-1,373	Closed	-$33K	–	2391
2017 Q1	$33K	Buy	+1,373	New	+$34.4K	﹤0.01%	1946
2013 Q4	–	Sell	-5,538	Closed	-$386K	–	1643
2013 Q3	$386K	Buy	+5,538	New	+$194K	0.01%	938

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HighTower Advisors's MACK Position: Q1 2019 in Review

HighTower Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2019, closing a stake of 19,129 shares — an estimated $58K sold.

HighTower Advisors first reported a position in MACK in Q3 2013 and held it in 8 quarters. The position peaked at $438K in Q3 2017. 54 funds tracked by Wall St. Rank hold MACK as of Q1 2019.

HighTower Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
HighTower Advisors sold 19,129 Merrimack Pharmaceuticals, Inc. shares in Q1 2019, an estimated $58K.
HighTower Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 8 quarters.
HighTower Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $438K in Q3 2017.
54 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2019.

Based on HighTower Advisors's 13F filing for Q1 2019, filed 15 May 2019.